ETF fact sheet · XLV · Health Care
State Street Health Care Select Sector SPDR ETF
The model values 60 of XLV's 60 holdings. At the median their price sits 1.9% below its fair value, and 57% of them are priced below it.
Among the holdings the model backs with medium or high evidence, the cheapest by its reckoning is Universal Health Services (UHS), priced 57.4% below fair value, and the priciest is Waters (WAT), priced 25.6% above fair value. That is the model's opinion, not advice.
The fund through Faircurve's model, from its run of 24 Oct 2026; closes to 27 Oct 2026.
XLV through the model
| Holding | Weight | 1D | Price vs fair value | Evidence |
|---|---|---|---|---|
| LLY Lilly (Eli) | 15.9% | +0.22% | 21.2% above | medium |
| JNJ Johnson & Johnson | 9.8% | +0.91% | 17.0% above | high |
| ABBV AbbVie | 7.7% | -0.10% | 2.2% below | high |
| UNH UnitedHealth Group | 5.8% | -0.08% | 0.5% above | medium |
| MRK Merck | 5.5% | +0.86% | 13.4% above | medium |
| TMO Thermo Fisher Scientific | 3.8% | +1.19% | 0.2% above | high |
| AMGN Amgen | 3.7% | +0.75% | 5.0% below | medium |
| GILD Gilead Sciences | 3.0% | +0.25% | 3.5% above | medium |
| ABT Abbott Laboratories | 2.7% | -1.70% | 2.5% below | high |
| PFE Pfizer | 2.6% | +0.03% | 10.7% below | medium |
| ISRG Intuitive Surgical | 2.4% | -1.27% | 18.9% above | high |
| DHR Danaher | 2.2% | -0.42% | 7.6% above | high |
| VRTX Vertex Pharmaceuticals | 2.1% | +0.68% | 3.7% above | medium |
| BMY Bristol Myers Squibb | 2.0% | -0.10% | 16.4% below | medium |
| CVS CVS Health | 1.8% | -1.51% | 3.2% below | medium |
| MDT Medtronic | 1.8% | -0.89% | 4.5% above | medium |
| MCK McKesson | 1.8% | -2.60% | at fair value | low |
| SYK Stryker | 1.6% | -1.54% | 12.5% above | high |
| ELV Elevance Health | 1.5% | -2.28% | 6.1% below | medium |
| CI Cigna | 1.3% | -2.45% | 29.1% below | medium |
| REGN Regeneron Pharmaceuticals | 1.2% | +1.04% | 4.9% below | medium |
| MRNA Moderna | 1.1% | +4.59% | 15.5% above | medium |
| HCA HCA Healthcare | 1.0% | -3.29% | 0.1% above | medium |
| BSX Boston Scientific | 1.0% | -1.14% | 12.9% below | medium |
| COR Cencora | 1.0% | -1.40% | 4.6% below | low |
| CAH Cardinal Health | 0.9% | -2.02% | 2.9% below | low |
| BDX Becton Dickinson | 0.8% | -0.69% | 0.8% above | high |
| EW Edwards Lifesciences | 0.8% | +0.29% | 13.1% above | high |
| HUM Humana | 0.8% | -0.57% | 10.6% above | medium |
| A Agilent Technologies | 0.7% | +0.87% | 5.9% below | high |
| VEEV Veeva Systems | 0.7% | -1.48% | 11.6% above | medium |
| IQV Iqvia | 0.7% | -0.75% | 30.5% below | high |
| WAT Waters | 0.7% | +2.76% | 25.6% above | high |
| IDXX Idexx Laboratories | 0.7% | -1.57% | 16.8% above | high |
| ILMN Illumina | 0.6% | +3.11% | 24.9% above | high |
| BIIB Biogen | 0.6% | +0.19% | 0.6% below | medium |
| RMD ResMed | 0.6% | -0.95% | 1.8% below | high |
| CNC Centene | 0.5% | +1.00% | 19.2% below | medium |
| ZTS Zoetis | 0.5% | -3.38% | 3.8% below | medium |
| MTD Mettler Toledo | 0.5% | +0.94% | 0.5% above | high |
| GEHC GE HealthCare | 0.5% | -1.21% | 6.4% below | high |
| DXCM Dexcom | 0.4% | -0.01% | 0.6% below | medium |
| WST West Pharmaceutical Services | 0.4% | +0.90% | 6.4% above | medium |
| DGX Quest Diagnostics | 0.4% | -0.16% | 18.6% below | medium |
| LH LabCorp | 0.4% | +0.38% | 19.3% below | medium |
| STE Steris | 0.3% | -0.71% | 3.3% above | medium |
| VTRS Viatris | 0.3% | +2.35% | 22.6% below | medium |
| INCY Incyte | 0.3% | +2.90% | 15.5% below | medium |
| ZBH Zimmer Biomet | 0.3% | -1.42% | 18.9% below | high |
| RVTY Revvity | 0.3% | +0.92% | 23.6% below | medium |
| CRL Charles River Laboratories | 0.2% | +0.44% | 29.5% below | high |
| BAX Baxter International | 0.2% | -1.46% | 6.7% above | medium |
| SOLV Solventum | 0.2% | -3.30% | 0.7% below | high |
| COO Cooper Companies (The) | 0.2% | -2.06% | 4.6% below | high |
| TECH Bio-Techne | 0.2% | -0.12% | 10.5% above | high |
| ALGN Align Technology | 0.2% | -0.20% | 23.3% below | high |
| PODD Insulet | 0.2% | +0.38% | 20.4% below | low |
| UHS Universal Health Services | 0.1% | -4.52% | 57.4% below | high |
| HSIC Henry Schein | 0.1% | -0.31% | 2.0% below | medium |
| DVA DaVita | 0.1% | -1.27% | 15.9% below | medium |
The 15 largest holdings by weight; the button shows all 60. Holdings as of 23 Oct 2026; closes to 27 Oct 2026; the model's run of 24 Oct 2026. Green is a price below the model's fair value, red above it. Not covered: the model does not value it. Withheld: its own checks flag the valuation.
How XLV has moved
| Period | Price return |
|---|---|
| One day | -0.06% |
| One week | -0.36% |
| One month | +4.95% |
| This year | +15.75% |
| One month against the S&P 500 | +4.24% |
One week is seven calendar days, one month 28. Beta 0.14 over the past 60 sessions: the fund moves about 0.1 times as much as the market.
What XLV is
State Street Health Care Select Sector SPDR ETF holds the S&P 500's health care companies.
| Expense ratio | 0.08% a year |
|---|---|
| Assets | $46.7 billion |
| Dividend yield | 1.42% ($2.55 paid over twelve months) |
| Holdings | 61 |
| Since | 1998 |
| Issuer | SPDR |
Sectors, share of the fund
| Healthcare | 99.1% |
|---|---|
| Technology | 0.7% |
| Cash & Others | 0.2% |